Literature DB >> 8875581

Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients.

C A Huseman1, J L Colombo, M A Brooks, J R Smay, N G Greger, P H Sammut, D M Bier.   

Abstract

The purpose of this study was to determine whether GH treatment of cystic fibrosis (CF) patients can result in an anabolic effect, i.e., increased weight gain, improved growth rate, nitrogen retention, and improved pulmonary function. Nine prepubertal endocrinologically normal CF patients (3 girls, 6 boys; chronological age (CA) 5.5-9.8 years, and bone age (BA) 4.5-9.0 years), received recombinant human growth hormone (rhGH) 0.3 mg/kg/week subcutaneously for a period of 12 months (N = 8) or 9 months (N = 1). Normal glucose tolerance was determined before treatment. Pulmonary function studies and anthropometric measurements were done every 3 months. Thyroid status, somatomedin C (SmC), BA, and routine chemistries were evaluated every 6 months. The pretreatment growth velocity averaged 5.7 +/- 0.3 (SE) cm/year and significantly increased to 7.8 +/- 0.4 (SE) cm/year during therapy, (P < 0.01). Standard deviation scores (SDS) for height significantly increased during rhGH therapy as compared with pretreatment, (P < 0.05). Weight of the patients during rhGH therapy did not significantly change during or after rhGH therapy. After therapy, all patients showed a significant increase in arm muscle area (AMA) and a significant decrement in arm fat area (AFA) (P < 0.01). Net nitrogen anabolism was negative in all subjects before therapy but became more positive in five patients during rhGH therapy. Three patients achieved positive nitrogen retention. SmC values significantly increased from a mean value of 0.62 +/- 0.1 (SE) U/ml to 1.6 +/- 0.6 (SE) U/ml after therapy. BA advanced 1.0 +/- 0.1 SE per year after treatment. Of the seven patients able to perform adequate pulmonary function testing, improvement occurred in FVC, FEV1.0, and PEFR in 5, 5, and 4 patients, respectively, but these changes did not reach statistical significance. We conclude that biosynthetic rhGH therapy had a significant anabolic effect in CF patients as shown by increased growth velocity, SmC values, increased protein and decreased fet stores, and a positive or less negative net nitrogen retention in five of the patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875581     DOI: 10.1002/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.0.CO;2-N

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  12 in total

Review 1.  Growth and growth charts in cystic fibrosis.

Authors:  Leena Patel; Moira Dixon; T J David
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

2.  Role of IGF-I, IGF-II and IGFBP-3 in lung function of males: the Caerphilly Prospective Study.

Authors:  Christopher J Green; Jeffrey M Holly; Charlotte E Bolton; Antony Bayer; Shah Ebrahim; John Gallacher; Yoav Ben-Shlomo
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

3.  Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth.

Authors:  Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

4.  A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis.

Authors:  Michael S Stalvey; Ran D Anbar; Michael W Konstan; Joan R Jacobs; Bert Bakker; Barbara Lippe; David E Geller
Journal:  Pediatr Pulmonol       Date:  2011-09-08

Review 5.  Appetite stimulants for people with cystic fibrosis.

Authors:  Diane McTavish; Judith Thornton
Journal:  Cochrane Database Syst Rev       Date:  2022-09-23

6.  Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis.

Authors:  A Schibler; R von der Heiden; P Birrer; P E Mullis
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

Review 7.  Growth hormone and exercise tolerance in patients with cystic fibrosis.

Authors:  Matthias Hütler; Ralph Beneke
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 8.  Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Authors:  Vidhu Thaker; Alexandra L Haagensen; Ben Carter; Zbys Fedorowicz; Brian W Houston
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 9.  Growth hormone treatment in children: review of safety and efficacy.

Authors:  Mark Harris; Paul L Hofman; Wayne S Cutfield
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 10.  Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Authors:  Vidhu Thaker; Ben Carter; Melissa Putman
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.